H.B. Fuller shifts to higher-margin medical adhesives; margins improve as debt climbs

Quick read - inside H.B. Fuller Company (NYSE: FUL)

What's happening inside
- Management is executing M&A to shift the portfolio to higher‑margin medical and specialty adhesives (GEM, Medifill, ND Industries, HS Butyl).
- Cost control and pricing improved gross margins despite a small revenue decline; restructuring plans from 2023 are winding down (expected complete by FY2026).
- The company continues active balance sheet management: large acquisitions funded by borrowings, continued share repurchases, and dividend payments.

Income statement - positives
- Net revenue (Q3 2025): $892.0M (Q3 2024: $917.9M) - modest decline but pricing helped offset volume.
- Gross profit (Q3 2025): $285.1M; gross margin improved to 32.0% from 30.0% (up 200 bps) driven by higher pricing, lower distribution costs and acquisition mix.
- Operating income (Q3 2025): $110.1M (vs. $104.3M) - segment operating strength, especially Engineering Adhesives.
- Net income attributable to H.B. Fuller (Q3 2025): $67.16M (Q3 2024: $55.36M) - EPS (diluted) Q3 2025: $1.22 vs. $0.98.
- Other income benefited from net defined benefit pension gains: other income, net Q3 2025 = $5.3M (up vs. $2.1M).
- Free cash flow YTD (9 months ended Aug 30, 2025): $62.2M (operating cash $156.8M less capex $94.6M).

Income statement - negatives / risks
- Revenue down year‑to‑date: Net revenue YTD Aug 30, 2025 = $2,578.8M vs. $2,645.5M (‑2.5%).
- Net income YTD fell: $122.24M (YTD 2024: $137.62M) - a drop of ~11.2% YTD.
- SG&A increased as % of revenue: Q3 SG&A 19.6% vs. 18.7% last year; YTD SG&A 21.0% vs. 19.9% - compensation and acquisition integration costs pressure margins.
- Interest expense remains material: Q3 interest expense $33.63M; YTD interest $100.54M; total long‑term debt $2,080.47M (Aug 30, 2025).
- Large amortization and acquisition accounting: amortization YTD $64.5M (Q3 $22.1M); goodwill and intangibles rose materially after acquisitions (goodwill $1,681.9M; intangibles net $829.4M).
- Discrete tax items impacted YTD taxes: $11.21M discrete tax expense in the nine months; effective tax rate excluding discrete items ~25.2% YTD.
- Derivative and translation volatility: accumulated other comprehensive loss still large at $(393.7)M; net investment hedge liabilities (cross‑currency swaps) mark‑to‑market liability $120.19M (Aug 30, 2025).
- Working capital and cash: cash & equivalents down to $122.46M from $169.35M (Nov 30, 2024); free cash flow down vs prior year ($62.2M vs $104.0M YTD).
- M&A cash outflow significant: $162.10M paid for acquisitions YTD; investing outflows net $(182.67)M YTD.

Key factual metrics & items to note
- Net revenue Q3 2025: $892,043 (thousands).
- Gross profit Q3 2025: $285,114 (thousands).
- Net income attributable to H.B. Fuller Q3 2025: $67,160 (thousands); diluted EPS Q3 2025: $1.22.
- Net income attributable YTD Aug 30, 2025: $122,236 (thousands); diluted EPS YTD: $2.21.
- Cash & cash equivalents (Aug 30, 2025): $122,458 (thousands).
- Total assets: $5,166,102 (thousands); total liabilities: $3,207,130 (thousands).
- Long‑term debt (Aug 30, 2025): $2,080,470 (thousands).
- Total debt / total capital ratio (Aug 30, 2025): 51.5% (vs 50.8% Nov 30, 2024).
- Free cash flow (nine months ended Aug 30, 2025): $62.2M (Net cash from ops $156.8M less capex $94.6M).
- Shares outstanding reported Sep 19, 2025: 54,088,889; common shares outstanding per balance sheet Aug 30, 2025: 54,043,300.
- Inventories (Aug 30, 2025): $502,956 (thousands); inventory days on hand: 78 days.
- Trade receivables (net): $563,579 (thousands); DSO: 57 days.
- Trade payables: $459,409 (thousands); DPO: 69 days.
- Restructuring costs incurred under 2023 Plans as of Aug 30, 2025: $69.7M (expected total ~$70-75M pre‑tax).
- Holdback liability (GEM & Medifill) fair value Aug 30, 2025: $33,570 (thousands).
- AOCI components (Aug 30, 2025): foreign currency translation $(182,626)k; net investment hedges $(90,934)k; accumulated other comprehensive loss total $(394,167)k.

Operational highlights by segment (Q3 2025)
- Engineering Adhesives: revenue $272.3M (+4.7% YoY Q3); operating income $46.85M (margin 17.2%) - strongest growth and margin expansion.
- Hygiene, Health & Consumable Adhesives: revenue $386.1M (‑1.0% Q3); operating income $46.49M (margin 12.0%) - medical adhesive acquisitions (GEM/Medifill) supporting the strategic shift.
- Building Adhesive Solutions: revenue $233.7M (+2.3% Q3); operating income $25.86M (margin 11.1%).

Bottom line - what to watch
- Watch cash generation vs. acquisition cadence: management is buying growth (medical & specialty) while debt remains >$2.0B and free cash flow is down YTD.
- Margin resilience is positive (gross margin +200 bps Q3) - can SG&A and integration costs be contained going forward?
- Interest costs and derivative exposures (cross‑currency swaps, AOCI volatility) could pressure earnings if rates or FX move unfavorably.
- Successful integration and expected synergies from recent acquisitions will determine whether higher goodwill/intangibles translate to sustained EPS growth.

Short verdict: H.B. Fuller (NYSE: FUL) is reshaping its portfolio toward higher‑margin, specialty adhesives and seeing margin improvement from pricing and cost actions. However, revenue is slightly down YTD, M&A and amortization lift non‑cash charges, debt is large and cash flow has softened - monitor integration results, cash conversion and interest/FX exposure for the next few quarters.